Oncotice (Bacillus Calmette-Guérin (Bcg), Tice)

Bacillus Calmette‑Guérin (BCG) Tice, the active ingredient in Oncotice, is a live bacterial vaccine presented as a sterile suspension for intravesical use. It is employed to treat non‑muscle invasive bladder cancer, including carcinoma in situ, in adult patients.

GNH USA supplies Oncotice as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Oncotice is used as an intravesical immunotherapy for bladder cancer, targeting the urothelial tumor environment.

- Non‑muscle invasive bladder cancer: reduces recurrence and progression after transurethral resection. - Carcinoma in situ of bladder: induces tumor regression and disease control. - High‑risk bladder cancer: provides adjunctive immune-mediated tumor eradication.

Oncotice may cause a range of adverse reactions, most of which are localized to the bladder or systemic inflammatory responses.

Common Side Effects: - Cystitis‑like symptoms: urinary frequency, urgency, and dysuria. - Hematuria: visible blood in urine. - Low‑grade fever and chills. - Fatigue or malaise. - Mild abdominal discomfort. - Transient urinary retention.

Serious or Rare Side Effects: - Systemic BCG infection or sepsis. - Disseminated mycobacterial disease. - Severe allergic reactions including anaphylaxis. - Bladder contracture or fibrosis. - Persistent high‑grade fever. - Renal impairment due to obstructive uropathy.

Prior to initiating therapy with Oncotice, several safety considerations should be observed.

- Patient selection: ensure absence of active urinary tract infection. - Immunocompromised status: avoid in patients with severe immunosuppression. - Concurrent chemotherapy: discontinue systemic cytotoxic agents before BCG instillation. - Monitoring: watch for signs of systemic infection or severe local reaction. - Pregnancy and lactation: not recommended due to insufficient safety data. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Oncotice can interact with other therapies that affect immune function or bacterial viability.

Major Interactions (Avoid): - Systemic chemotherapy administered within two weeks of BCG. - High‑dose corticosteroids or other potent immunosuppressants. - Concurrent administration of other live vaccines.

Moderate Interactions (Monitor Closely): - Intravesical chemotherapy agents given shortly before or after BCG. - Antibiotics that may reduce BCG viability (e.g., fluoroquinolones). - Antifungal agents with activity against mycobacteria. - Immunomodulatory biologics used for other conditions.